Independent biopharmaceutical company Specialised Therapeutics Asia has added three new endocrinology therapies to its specialist portfolio, following an exclusive distribution agreement with Danish company Ascendis Pharma. Under the terms of the agreement, ST will commercialize Ascendis Pharma’s weekly injectable pediatric human growth hormone treatment SKYTROFATM, hypoparathyroidism treatment YORVIPATHTM and investigational achondroplasia therapy TransCon CNP. The agreement spans ST’s key regions of Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
- Ascendis Pharma announces new analyses from OLE portions of ACcomplisH
- Ascendis Pharma price target raised to $202 from $200 at Wedbush
- Ascendis Pharma price target raised to $133 from $110 at TD Cowen
